# PAQ Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/paq-therapeutics

- Industry: Biotechnology
- Headquarters: Burlington, US
- Website: www.paqtx.com
- Total disclosed funding: $111M
- Latest round: Series B (Jan 26, 2026)
- Investors on record: 11

## About

Based in Massachusetts, US, and founded in 2020, PAQ Therapeutics Inc. operates as a biotechnology company that develops novel therapies through autophagosome-tethering compound (ATTECs) technology. The company was co-founded by Nan Ji, Boxun Lu, and Huaixiang Hao. In January 2026, PAQ Therapeutics Inc. raised USD 38 million in Series B+ funding led by Sherpa Healthcare Partners, with participation from Huagai Capital, MSA Capital, MRL Ventures Fund, Nest.Bio Labs, and MPC.

PAQ Therapeutics Inc. platform focuses on a genetic neurodegenerative disorder to treat a disease caused by protein and non-protein substrates, such as mitochondria, lipids, and pathogens. The company's line of products includes ATTEC (autophagosome-tethering compound) that develops small molecules for autophagosome and the disease-associated parts of a cell. Autophagy is waste management and recycling system that disposes of the dysfunctional components of a cell.
The company’s revenue is generated by research funding and partnership/financing proceeds that support clinical development activities, because public sources emphasize venture financing and clinical program advancement but do not disclose operating revenue details. The January 2026 funding will be used to advance preclinical research of its core pipeline and optimize its platform technology.

## Funding rounds

- Series B, Jan 26, 2026, $38M — MSA Capital, Huagai Capital, MPC, Nest.Bio Labs, Sherpa Healthcare Partners, MRL Ventures Fund
- Series B, May 7, 2025, $39M — Johnson & Johnson Innovation, Lilly Asia Ventures, BioTrack Capital, Sherpa Healthcare Partners, MRL Ventures Fund, Bayland Capital
- Series A, Jul 15, 2021, $30M — MSA Capital, Huagai Capital, MPC, Nest.Bio Ventures, Sherpa Healthcare Partners, MRL Ventures Fund
- Seed, Jun 1, 2020, $4M — MPC, Nest.Bio Ventures

## Investors

- MPC — Seed, Series A, Series B
- Nest.Bio Ventures (https://capitalatlas.ai/funds/nest-bio-ventures) — Seed, Series A
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series A, Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A, Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A, Series B
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series B
- Bayland Capital — Series B
- Nest.Bio Labs (https://capitalatlas.ai/funds/nest-bio-labs) — Series B